M6620 + carboplatin

M6620 (VX-970, berzosertib) is a first-in-class, potent and selective small molecule inhibitor of Ataxia Telangiectasia and Rad3-related protein (ATR), a serine/threonine-specific protein kinase involved in the DNA damage response. Carboplatin is a platinum-based chemotherapeutic that causes DNA crosslinking and double-strand breaks. The combination of M6620 and carboplatin is being developed as a novel strategy to enhance the anti-tumor effects of carboplatin by inhibiting ATR-mediated repair of DNA damage caused by platinum agents. This combination has demonstrated acceptable safety and preliminary antitumor activity in phase I/II studies, particularly in cancers with homologous recombination deficiency (such as BRCA1/2 mutations) and platinum-resistant tumors. M6620 is usually administered intravenously on days 2 and 9 of a 21-day cycle after carboplatin administration on day 1. The combination is under investigation for metastatic castration-resistant prostate cancer, ovarian cancer, and other solid tumors[1][2][3][4][5].

Brand names

berzosertib (for M6620)

Other names

berzosertib + carboplatin